Metrics as of 10/16/2026, 02:29 AM (Berlin time), refresh in progress.
GRAIL Stock
GRAIL Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Joshua J. Ofman
- Employees
- 910
- Market cap
- $6.1 B
- IPO
- 12/06/2024
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic…
GRAIL stock: price history
1D
-3.0%
1W
+2.1%
1M
+78.5%
6M
+173.8%
YTD
+58.3%
1Y
+79.4%
2Y
+866.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~96% stronger price swings than usual
GRAIL stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
GRAIL Inc. operates in the field of health diagnostics and specializes in early cancer detection through innovative testing procedures such as the Galleri test for individuals over 50 years of age. In addition to diagnostic tools for clinical suspected cases, the company offers comprehensive services in the research sector, including support for clinical trials and therapy development. A key technological element is the methylation-based platform for precision oncology, which can be used for risk assessment and monitoring of recurrences. Business activities are currently heavily concentrated on the US market, while international revenues represent a smaller portion.
- Revenue model
- Transactional
- Recurring revenue
- Medium
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about GRAIL
Analyst assessment of GRAIL
PRICE TARGET LOW
US$56.00
CONSENSUS
US$107.88
MEDIAN
US$109.00
PRICE TARGET HIGH
US$175.00
0
STRONG BUY
5
BUY
3
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 13/10/2026
GRAIL stock metrics
P/E
-13.89
P/B
2.3
EV/EBITDA
-16.27
RETURN ON EQUITY
-4.3%
NET MARGIN
-246.7%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.1%
FLOAT SHARES
42,035,347
AVG. DAILY VOLUME (30D)
1,301,230
Insider transactions (SEC)
MIZELL STEVEN
SUMME GREGORY L
CHASE WILLIAM J
Ofman Joshua J.
Ofman Joshua J.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.0%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about GRAIL stock
What does GRAIL do?
GRAIL Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Joshua J. Ofman, the company employs around 910 people.
The IPO was on 12/06/2024; the stock trades on NASDAQ under the ticker GRAL.
What do analysts say about GRAIL stock?
8 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$107.88, ranging from US$56.00 to US$175.00, with a median of US$109.00.
This is an external assessment, not a statement by Market Jury.
When does GRAIL report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 96% stronger than usual.
Does GRAIL pay a dividend?
No, GRAIL currently does not pay a dividend.
Which stocks are comparable to GRAIL?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get GRAIL stock analyzed?
Clicking "Analyze stock" lets five strategies assess GRAIL against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.